Press Release Archive

07.22.2012

Pfizer Reports Top-Line Results of Study of Lyrica’s Effect on Male Reproduction Conducted as a Post-Approval Commitment Required by the U.S. Food and Drug Administration

07.19.2012

Pfizer’s Crizotinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Adults With Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer In The EU

07.19.2012

Pfizer and Northwestern University Win LYRICA® Patent Case in Delaware District Court

07.18.2012

European Medicines Agency Accepts Regulatory Submission For Bazedoxifene/Conjugated Estrogens For The Treatment Of Symptoms Associated With Menopause And Osteoporosis

07.11.2012

VERASTEM ACQUIRES CLINICAL-STAGE FAK INHIBITOR FROM PFIZER

06.28.2012

Pfizer Declares A 22-Cent Third-Quarter 2012 Dividend

06.25.2012

Pfizer Invites Public to View and Listen to Webcast of July 31 Conference Call with Analysts

06.24.2012

Bristol-Myers Squibb and Pfizer Receive Complete Response Letter from U.S. Food and Drug Administration for ELIQUIS® (apixaban)

06.21.2012

EMA Adopts Opinion On Taliglucerase Alfa Marketing Authorization Application

06.20.2012

FDA Approves Lyrica For The Management Of Neuropathic Pain Associated With Spinal Cord Injury Based On Priority Review

06.20.2012

Pfizer Statement Regarding Prevnar 13® Receiving ACIP Recommendation for Prevention of Pneumococcal Disease in Adults With Immunocompromising Conditions

06.18.2012

Pfizer Announces Positive Results From Phase 3 Study PROFILE 1007 Evaluating XALKORI® (crizotinib) In Previously Treated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer